Core Viewpoint - The company Aihuilong (688575.SH) is collaborating with Brain Machine Star Chain on product development, but the related medical device registration certificate has not yet been obtained, with expected revenue generation not anticipated before November 2026 [1] Group 1: Collaboration and Development - The collaboration with Brain Machine Star Chain focuses on non-invasive technology paths, which are currently in the early stages of development [1] - The estimated research and development investment for the related projects is around 30 million yuan [1] Group 2: Financial Implications - Brain Machine Star Chain is a relatively new and small-scale company, which may require expanded financing to advance subsequent research and development [1] - The company does not rule out small-scale equity investments or joint ventures in the short term, but the expected investment amount is not anticipated to have a significant impact on the company [1]

Core Viewpoint - The company announced that its collaboration with Brain-Computer Starlink has not yet obtained medical device registration certification, with revenue expected to be generated by 2026 at the earliest [1] Group 1: Collaboration and Investment - The collaboration focuses on non-invasive technology and is still in the early stages, with an estimated investment of around 30 million yuan [1] - The company plans to invest no more than 15 million yuan in Brain-Computer Starlink [1] Group 2: Financial Performance - For the first three quarters of 2025, the company's revenue was 1.287 billion yuan, a year-on-year decrease of 7.69% [1] - The net profit for the same period was 60.42 million yuan, down 72.36% year-on-year, primarily due to industry policies and losses from trading financial assets [1] Group 3: Stock Price Movement - On January 6, the company's stock price experienced unusual fluctuations, and an internal investigation revealed that the Deputy Director of the President's Office, Yao Lan, sold 200 shares on January 5, which was unrelated to insider information [1]

Core Insights - The brain-computer interface (BCI) industry is entering a "golden development period," characterized by significant advancements from laboratory innovations to clinical applications [1][2][3] Group 1: Technological Advancements - In 2025, significant milestones were achieved in BCI technology, including the first clinical trials of flexible micro-invasive BCI systems and the first intervention-assisted trials for restoring limb function [2][3] - Three main technological routes are developing in parallel: invasive, semi-invasive, and non-invasive techniques, with invasive methods being central to medical rehabilitation due to their high signal acquisition precision [3][4] - The semi-invasive BCI system developed by Borui Kang Technology requires only a small hole in the skull for implantation, allowing patients to control movements through thought [4] Group 2: Clinical Applications and Breakthroughs - Clinical breakthroughs include the successful restoration of walking in patients with severe spinal cord injuries through innovative BCI technologies [3][4] - A variety of new BCI applications are emerging, such as a visual reconstruction system for visually impaired patients and a wireless, fully implanted BCI product that has completed its first clinical trial [10][11] Group 3: Industry Growth and Policy Support - The establishment of pricing regulations for BCI services by the National Medical Insurance Administration marks a significant step in integrating this technology into public healthcare [6][8] - Various regions, including Shanghai and the Guangdong-Hong Kong-Macau Greater Bay Area, are forming BCI innovation clusters to enhance industry capabilities and foster collaboration among enterprises, hospitals, and research institutions [7][8] Group 4: Future Prospects - Experts predict that 2026 will be a pivotal year for the BCI industry, with advancements in multi-disciplinary integration, clinical scalability, and diverse application scenarios [9][10] - The anticipated mass production of certain BCI devices will pave the way for a diversified application ecosystem, enhancing the potential for widespread commercial use [10][11]